Share chart BioMarin Pharmaceutical
Extended chart
Simple chart
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. — американская биотехнологическая компания со штаб-квартирой в Сан-Рафаэле, Калифорния . У него есть офисы и помещения в США , Южной Америке , Азии и Европе . Основным направлением деятельности и исследованиями BioMarin является заместительная терапия ферментами (ФЗТ). more detailsMain settings
IPO date
1999-07-23
ISIN
US09061G1013
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 4.51 | 3 |
| P/BV | 2.28 | 6 |
| P/E | 30.16 | 5 |
Efficiency
| Title | Value | Grade |
| ROA | 6.17 | 2 |
| ROE | 8.05 | 3 |
| ROIC | 0.79 | 1 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 0.9265 | 9 |
| Debt/Ratio | 0.0862 | 10 |
| Debt/Equity | 0.2352 | 10 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 53.44 | 7 |
| Yield Ebitda, % | -11125.9 | 0 |
| Yield EPS, % | -51.56 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 57.55 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 59.41 $ | 0 $ | 0 $ | -3.13 % | 0 % | 0 % |
| Month | 62.74 $ | 57.55 $ | 59.93 $ | -8.27 % | 0 % | 0 % |
| Three month | 69.01 $ | 55.89 $ | 72.83 $ | -16.6 % | 0 % | 0 % |
| Half a year | 64.88 $ | 55.89 $ | 72.83 $ | -11.3 % | 0 % | 0 % |
| Year | 75.52 $ | 55.89 $ | 93.84 $ | -23.8 % | 0 % | 0 % |
| 3 years | 72.42 $ | 55.89 $ | 117.27 $ | -20.53 % | 0 % | 0 % |
| 5 years | 82.93 $ | 55.89 $ | 131.03 $ | -30.6 % | 0 % | 0 % |
| 10 years | 80.61 $ | 55.89 $ | 149.09 $ | -28.61 % | 0 % | 0 % |
| Year to date | 66.01 $ | 55.89 $ | 72.83 $ | -12.82 % | 0 % | 0 % |
Insider trading
| Insider | Transaction date | Date of disclosure | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
| Burkhart Erin GVP, Chief Accounting Officer |
20.05.2025 | 20.05.2025 | Sale | 59.31 | 105 928 | 1786 | 0 | 0 | link |
| Burkhart Erin GVP, Chief Accounting Officer |
19.03.2025 | 20.03.2025 | Sale | 71.52 | 92 618 | 1295 | 0 | 0 | link |
| Burkhart Erin GVP, Chief Accounting Officer |
24.02.2025 | 25.02.2025 | Sale | 68.38 | 91 903 | 1344 | 0 | 0 | link |
| Guyer Charles Greg Officer |
12.11.2024 | 12.11.2024 | Purchase | 66.37 | 350 301 | 5278 | 0 | 0 | link |
| BIENAIME JEAN JACQUES Director |
10.05.2024 | 13.05.2024 | Sale | 81.14 | 1 622 800 | 20000 | 0 | -0.01 | link |
| BIENAIME JEAN JACQUES Director |
10.05.2024 | 13.05.2024 | Purchase | 63.1 | 1 262 000 | 20000 | 0 | 0.01 | link |
| BIENAIME JEAN JACQUES Director |
09.05.2024 | 13.05.2024 | Sale | 81.62 | 1 632 400 | 20000 | 0 | -0.01 | link |
| BIENAIME JEAN JACQUES Director |
09.05.2024 | 13.05.2024 | Purchase | 63.1 | 1 262 000 | 20000 | 0 | 0.01 | link |
| BIENAIME JEAN JACQUES Director |
12.04.2024 | 15.04.2024 | Sale | 91.26 | 1 825 200 | 20000 | 0 | -0.01 | link |
| BIENAIME JEAN JACQUES Director |
12.04.2024 | 15.04.2024 | Purchase | 63.1 | 1 262 000 | 20000 | 0 | 0.01 | link |
| BIENAIME JEAN JACQUES Director |
11.04.2024 | 15.04.2024 | Sale | 90.99 | 1 819 800 | 20000 | 0 | -0.01 | link |
| BIENAIME JEAN JACQUES Director |
11.04.2024 | 15.04.2024 | Purchase | 63.1 | 1 262 000 | 20000 | 0 | 0.01 | link |
| Burkhart Erin GVP, Chief Accounting Officer |
10.04.2024 | 12.04.2024 | Sale | 90 | 205 740 | 2286 | 0 | 0 | link |
| BIENAIME JEAN JACQUES Director |
10.01.2024 | 11.01.2024 | Sale | 96.38 | 963 800 | 10000 | 0 | -0.01 | link |
| BIENAIME JEAN JACQUES Director |
10.01.2024 | 11.01.2024 | Purchase | 63.1 | 631 000 | 10000 | 0 | 0.01 | link |
| BIENAIME JEAN JACQUES Director |
09.01.2024 | 11.01.2024 | Sale | 98.19 | 981 900 | 10000 | 0 | -0.01 | link |
| BIENAIME JEAN JACQUES Director |
09.01.2024 | 11.01.2024 | Purchase | 63.1 | 631 000 | 10000 | 0 | 0.01 | link |
| Davis George Eric EVP, Chief Legal Officer |
13.12.2023 | 14.12.2023 | Sale | 95.3 | 1 311 710 | 13764 | 0 | -0.01 | link |
| BIENAIME JEAN JACQUES Chief Executive Officer |
08.08.2023 | 09.08.2023 | Sale | 88.29 | 529 740 | 6000 | 0 | 0 | link |
| Davis George Eric EVP, Chief Legal Officer |
08.08.2023 | 09.08.2023 | Sale | 89.42 | 983 620 | 11000 | 0 | -0.01 | link |
| BIENAIME JEAN JACQUES Chief Executive Officer |
07.08.2023 | 09.08.2023 | Sale | 88.1 | 352 400 | 4000 | 0 | 0 | link |
| BIENAIME JEAN JACQUES Chief Executive Officer |
10.05.2023 | 11.05.2023 | Sale | 94.85 | 2 845 500 | 30000 | 0 | -0.02 | link |
| BIENAIME JEAN JACQUES Chief Executive Officer |
10.05.2023 | 11.05.2023 | Purchase | 67.81 | 2 034 300 | 30000 | 0 | 0.02 | link |
| BIENAIME JEAN JACQUES Chief Executive Officer |
09.05.2023 | 11.05.2023 | Sale | 94.93 | 2 847 900 | 30000 | 0 | -0.02 | link |
| BIENAIME JEAN JACQUES Chief Executive Officer |
09.05.2023 | 11.05.2023 | Purchase | 67.81 | 2 034 300 | 30000 | 0 | 0.02 | link |
| BIENAIME JEAN JACQUES Chief Executive Officer |
06.04.2023 | 10.04.2023 | Sale | 96.13 | 961 300 | 10000 | 0 | -0.01 | link |
| BIENAIME JEAN JACQUES Chief Executive Officer |
06.04.2023 | 10.04.2023 | Purchase | 67.81 | 678 100 | 10000 | 0 | 0.01 | link |
| Ajer Jeffrey Robert EVP, Chief Commercial Officer |
25.01.2023 | 27.01.2023 | Sale | 115.7 | 5 669 300 | 49000 | 0 | -0.03 | link |
| Ajer Jeffrey Robert EVP, Chief Commercial Officer |
25.01.2023 | 27.01.2023 | Purchase | 67.81 | 3 322 690 | 49000 | 0 | 0.03 | link |
| BIENAIME JEAN JACQUES Chief Executive Officer |
14.10.2022 | 18.10.2022 | Sale | 89.89 | 359 560 | 4000 | 0 | 0 | link |
Main owners
| Institutions | Volume | Share, % |
| PRIMECAP Management Company | 18 414 374 | 9.76 |
| Vanguard Group Inc | 18 050 062 | 9.57 |
| Blackrock Inc. | 14 681 644 | 7.78 |
| Dodge & Cox Inc | 13 994 063 | 7.42 |
| Capital Research Global Investors | 10 774 641 | 5.71 |
| State Street Corporation | 6 730 515 | 3.57 |
| Ameriprise Financial, Inc. | 5 419 366 | 2.87 |
| Barclays PLC | 5 288 893 | 2.8 |
| Viking Global Investors, L.P. | 4 889 454 | 2.59 |
| Avoro Capital Advisors LLC | 4 300 000 | 2.28 |
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
| VictoryShares Nasdaq Next 50 ETF | 1.38305 | 3.94 | 0.18 |
| iShares Evolved U.S. Innovative Healthcare ETF | 1.35 | 0.000586 | 0.18 |
| Future Tech ETF | 1.30612 | -18.13 | 0.35 |
| Principal Healthcare Innovators ETF | 1.30612 | -3.92 | 0.35 |
| IQ Engender Equality ETF | 1.03522 | 7.62 | 0.45 |
| GraniteShares XOUT U.S. Large Cap ETF | 0.86381 | -25.71 | 0.60 |
| Syntax Stratified MidCap ETF | 0.34133 | -1.54 | 0.35 |
| iShares Morningstar Mid-Cap Growth ETF | 0.24673 | 441.88 | 0.06 |
| iShares Morningstar Mid-Cap ETF | 0.12333 | 252.83 | 0.04 |
| iShares Morningstar Large-Cap Growth ETF | 0.05463 | 264.7 | 0.04 |
| iShares Morningstar Large-Cap ETF | 0.0266 | 184.21 | 0.03 |
| Columbia U.S. ESG Equity Income ETF | 0.02348 | -3.6 | 0.35 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Brian R. Mueller | CFO & Executive VP | 1.15M | 1974 (51 year) |
| Mr. George Eric Davis | Executive VP, Chief Legal Officer, General Counsel & Secretary | 1.23M | 1971 (54 years) |
| Ms. Erin Burkhart | Group VP & Chief Accounting Officer | N/A | 1979 (46 years) |
| Mr. Alexander Hardy | President, CEO & Director | N/A | 1969 (56 years) |
| Dr. C. Greg Guyer Ph.D. | Executive VP & CTO | 1962 (63 years) | |
| Dr. Kevin Eggan Ph.D. | Chief Scientific Officer & Senior VP of Research and Early Development | ||
| Traci McCarty | Group Vice President of Investor Relations | ||
| Ms. Humaira Serajuddin | Senior VP & Chief Marketing Officer | ||
| Ms. Amy Wireman | Executive VP & Chief People Officer |
About company
Address: United States, San Rafael, 770 Lindaro Street - Open in google maps, Open in yandex maps
Website: http://www.biomarin.com
Website: http://www.biomarin.com
